Bayer's new five-year-contraceptive submitted for EU and US marketing authorization

BayerBayer has submitted an application for marketing authorization in both the European Union and in the United States for LCS-16, a new low-dose levonorgestrel-releasing intrauterine system (LNG-IUS) which is directly placed in the uterus for contraception for up to five years. Long-acting contraception is one of the most effective methods of birth control. An LNG-IUS can be removed at any time and offers rapid return to a woman's usual level of fertility after removal.

"As a leader in Women's Healthcare we are committed to continuously advance our portfolio of innovative contraceptive methods to meet the needs of a broad range of women," said Dr. Joerg Moeller, Member of the Bayer HealthCare Executive Committee and Head of Global Development. "An intrauterine system does not only bring the advantage that women do not have to think about their contraception every day, but also that it contains fewer hormones than other hormonal contraceptive options like the pill or implant. With the application for marketing authorization for LCS-16, we hope we will be able to offer women an additional option of a reliable and convenient long-acting reversible contraception that contains the lowest available dose of hormones for up to five years."

Data from Phase III clinical trials, including 574 nulliparous and 878 parous women from North America and several European countries have demonstrated that LCS-16 is highly effective and well tolerated regardless of age and parity. The primary endpoint of the Phase III clinical trial program was contraceptive efficacy assessed by the Pearl index. The data showed that the new IUS is more than 98.5 percent effective in preventing pregnancy. Moreover, LCS-16 was generally well tolerated, with no unexpected adverse events reported. Low incidences of ectopic pregnancy, pelvic inflammatory disease, expulsion of the device from the uterus and uterine perforation were seen.

About LCS-16
LCS-16 is a small, flexible plastic T-shaped device. Once placed in the uterus, it releases a low dose of the progestogen levonorgestrel directly into the uterus and provides effective birth control for up to five years. It also offers rapid return to a woman's usual level of fertility after removal.

With a Pearl-Index of 0.31 after three years and 0.29 after five years based on reported efficacy in clinical trials, LCS-16 provides highly effective, long-acting contraception for women who desire a low-dose contraceptive option for up to five years.

About Bayer in Women's Healthcare
Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. With a long heritage in Women's Healthcare, Bayer offers a wide range of effective short- and long-acting birth control methods as well as therapies for menopause management and gynecological diseases with several other compounds in various stages of clinical development. Together, these products reflect the company's approach to research, which prioritizes targets and pathways with the potential to impact the way how women's health related conditions are treated.

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care and agriculture. Bayer HealthCare, a subgroup of Bayer AG with annual sales of around EUR 20.0 billion (2014), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 60,700 employees (Dec 31, 2014) and is represented in more than 100 countries.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...

Pfizer and Astellas amend clinical research protoc…

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced amendments to the protocols for two registratio...